Makoto Naganuma received grants from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Kyorin Pharmaceutical Co., Ltd., and lecture fees from Tanabe Pharma Corporation, AbbVie GK, Kyorin Pharmaceutical Co., Ltd. Kissei Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., EA Pharma Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., and Mochida Pharmaceutical Co., Ltd., Corporation, AbbVie GK outside the submitted work. Taku Kobayashi received lecture fees from Takeda Pharmaceutical Co. Ltd. Activaid, Alfresa Pharma Corporation, Zeria Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Abbie GK, Pfizer Japan Inc., Janssen Pharmaceutical K.K., Thermo Fisher Diagnostics K.K., and JIMRO Co., Ltd., and received research grants from Abbvie GK, Activaid, Alfresa Pharma Corporation, JMDC Inc., Gilead Sciences, Inc., Nippon Kayaku Co., Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Ferring Pharmaceuticals, and Bristol-Myers Squibb, and received scholarship contributions from Mitsubishi Tanabe Pharma Corporation, Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and belonged to the study group sponsorship by Otsuka Holdings, Abbvie GK, EA Pharma Co., Ltd., Zeria Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., and Mochida Pharmaceutical Co., Ltd. Advisory/consultancy fees were obtained from Janssen Pharmaceutical K.K., EA Pharma Co., Ltd., KISSEI Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Activaid, Pfizer Japan Inc., Nippon Kayaku Co., Ltd., Alfresa Pharma Corporation, Kyorin Pharmaceutical Co., Ltd., Abbie GK, Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Celltrion, Gilead Sciences, Inc., Ferring Pharmaceuticals, Eli Lilly Japan K.K., and Daiichi Sankyo Company outside the submitted work. Reiko Kunisaki received research grant and lecture fees from AbbVie, Astellas, EA Pharma, Janssen Pharmaceutical, Kyorin, Nippon Kayaku, Mitsubishi Tanabe, Takeda, Zeria, Janssen, Eli Lilly, and Pfizer outside the submitted work. Hisashi Shiga received lecture fees from Mitsubishi Tanabe Pharma Corp., AbbVie Inc., EA Pharma Co. Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co. Ltd., and Pfizer Inc outside the submitted work. Shingo Kato received lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K outside the submitted work. Motohiro Esaki received research grants from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., AbbVie GK, Kyorin Pharmaceutical Co., Ltd., and Alfresa Pharma Corporation, and lecture fee from Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., AbbVie GK, Pfizer Japan Inc. and EA Pharma Co., Ltd. outside the submitted work. Masayuki Saruta received grants from EPS Corporation and scholarship grants form Mochida Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd. and lecture fees from Abbvie GK, EA Pharma Co., Ltd., Janssen Pharmaceutical, GK, Mochida Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., EA Pharma Co., Ltd outside the submitted work. Kaoru Yokoyama received lecture fees from Takeda Pharmaceutical Co., Ltd. and Mochida Pharmaceutical Co., Ltd outside the submitted work. Yoshikazu Tsuzuki received grants from AbbVie GK and Mitsubishi Tanabe Pharma Corporation, and lecture fee from AbbVie GK, EA Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer Japan Inc. outside the submitted work. Mikihiro Fujiya reports grants, personal fees from EA Pharma Co., Ltd., grants, personal fees from Ayumi Pharmaceutical Corporation, grants, personal fees from AbbVie Inc, grants, personal fees from Otsuka Pharmaceutical Co., Ltd., grants, personal fees from Zeria Pharmaceutical Co., Ltd., grants, personal fees from Nippon Kayaku Co., Ltd., grants, personal fees from Nobelpharma Co., Ltd., grants, personal fees from Pfizer Inc, grants, personal fees from Janssen Pharmaceutical K.K., grants, personal fees from Kyorin Pharmaceutical Co., Ltd., grants, personal fees from Mochida Pharmaceutical Co., Ltd, grants, personal fees from Daiichi Sankyo Company, Limited, grants, personal fees from Mitsubishi Tanabe Pharma Corporation, grants, personal fees from Takeda Pharmaceutical Company Limited, grants, personal fees from Yakult Honsha Co., Ltd., personal fees from OLYNPUS Co., Ltd., personal fees from celltrionhealthcare.jp, personal fees from Alfresa Pharma Corporation, personal fees from Mylan Inc., personal fees from Boston Scientific Corporation, personal fees from Covidien Japan, Inc., personal fees and non-financial support from FUJIFILM Corporation, grants from Fuji Chemical Industries Co., Ltd., grants from JIMRO Co., Ltd., and grants from Kamui Pharma. Inc. Tadakazu Hisamatsu has performed joint research with Alfresa Pharma Co., Ltd. and EA Pharma Co., Ltd.; received grant support from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., AbbVie GK, JIMRO Co., Ltd., Zeria Pharmaceutical Co., Ltd., Daiichi-Sankyo, Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., and Mochida Pharmaceutical Co., Ltd.; and received consulting and lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Celgene K.K., EA Pharma Co., Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., KISSEI pharmaceutical Co., LTD., Ltd., Eli Lilly & Co., Gilead Sciences, Inc., and Pfizer Inc outside the submitted work.

We would also like to thank Editage (www.editage.jp) for English language editing.